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Menn P, Sun J, Holle R
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OBJECTIVES: To develop a Markov model for an economic
evaluation of a hypothetical intervention in chronic obstructive
pulmonary disease (COPD), to implement it in TreeAge and
ARENA in order to ensure its technical validity and to compare
ease of implementation. METHODS: We used a 7-state Markov
model (disease stages I to IV according to GOLD classiﬁcation,
post-surgery, post-transplantation and death) with a time frame
of 60 years to assess incremental costs (€) and effects (life-years
gained, LYG). Applying identical assumptions regarding transi-
tions and costs, we ran Monte Carlo simulations with 10,000
patients for 100 replications in both packages. Additionally, we
calculated expected values for the TreeAge model. RESULTS: In
TreeAge, the simulation resulted in higher incremental costs and
effects compared to ARENA (p < 0.0001). Standard errors in
both packages were equal for effects, but slightly higher for costs
in ARENA. For the TreeAge model, averaged simulated values of
both costs and effects were close to the expected values, indicat-
ing adequate sample size. Run-time was slightly shorter in
ARENA. Yet determining cost-effectiveness values was more
convenient using TreeAge. CONCLUSION: Building a standard
Markov model for cost-effectiveness calculations appears more
comfortable in TreeAge. Useful tools for calculating and plotting
the results of an economic evaluation are available and can easily
be applied. In ARENA, users must implement these features
themselves, yet the user is more ﬂexible when classical Markov
assumptions no longer hold.
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OBJECTIVES: Direct preference elicitation is uncommon in
clinical trials of COPD treatments. Investigators have created an
algorithm that estimates EQ-5D preference weights from the St.
George’s Respiratory Questionnaire (SGRQ) to permit the
calculation of QALYs. METHODS: Using data from a placebo
controlled randomized trial comparing three regimens: 1) tiotro-
pium plus placebo; 2) tiotropium plus salmeterol; and 3) tiotro-
pium plus salmeterol/ﬂuticasone) in COPD, we examined the
validity of estimated EQ-5D scores from the SGRQ. RESULTS:
A total of 351 patients with complete SGRQ scores at each point
in the trial were included in the analysis. The mean values of the
SGRQ and the estimated EQ-5D revealed similar pattern across
the three treatments over time. A scatterplot of the SGRQ scores
versus the EQ-5D scores showed that although there was an
underlying linear relationship, it was somewhat “stepped” as the
conversion algorithm results in the estimation of the same
EQ-5D utility value for a number of SGRQ scores. Given that the
minimally clinical important difference (MCID) of the SGRQ is
4, it would be possiblethat one might lose an MCID response
when converting to the EQ-5D (whose MCID is 0.03). This was
not the case in 85% of the SGRQ MCID responders. Finally, to
see if any of the above made a difference statistically, the SGRQ
scores and the estimated EQ-5D scores were compared at the end
of the study (52 weeks). For the predicted mean EQ-5D utilities,
treatment arms 1 and 3 were signiﬁcantly different. However,
when using the SGRQ, treatment arms 1 and 3 and treatment
arms 1 and 2 were signiﬁcantly different. CONCLUSION: The
conversion algorithm was judged to be sufﬁcient. However, use
of the algorithm resulted in a reduction in discriminatory ability
of the estimated EQ-5D as compared to the SGRQ.
RESPIRATORY DISORDERS—Patient Reported Outcomes
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OBJECTIVES: Evaluate diagnostic validity of indirect methods
of compliance assessment (Gold standard: number of doses
applied per day) in COPD (Chronic Obstructive Pulmonary
Disease) patients with inhaled regular medication. METHODS:
Cohort study of 98 patients with follow up of sis months. Vari-
ables: age, gender, educational level, comorbidity, COPD staging
(by SEPAR recommendations), prescribed drugs, and indirect
methods for compliance assessment (Morisky-Green test, Batalla
test), and count of number of doses applied per day as gold
standard (electronic count or perforated pills number).
RESULTS: Predominace of males, with mean age of 69 years (CI
95% 67–72); low cultural level, 23% smokers (28 cigarrettes/day
[CI 95%, 26.73–30.67]) Overweight (Body Mass Index
29 kg/m2 [CI 95%, 29.1–30.1]). Seventy-ﬁve percent of patients
are in mild-moderate severity stage with predominance of mixed
respiratory pattern; FEV1 (mean) 53.99 (IC 95% 50.07–57.91).
A total of 1.67 exacerbations per year [IC 95%, 1.31–2.03].
Pharmacological treatment: inhaled anticholinergic 89.8%
patients inhaled beta2-adrenérgic 86.7% patients, inhaled corti-
costeroids 70.4% patients; xantins 16.3% patients, oxygen
therapy 5.1% patients; oral corticosteroids 1% patients, muco-
lytics 2% patients. Sixty-six percent patients (67.3%) completed
follow-up. Compílance prevalence: gold standard: 57.6%;
Morisky-Green test 50.8% sensibility 58%, speciﬁcity 67%, like-
lihood ratio for positive result 1.76; Batalla test 63.1%; sensibil-
ity 83%, speciﬁcity 70%, likelihood ratio for positive result 2.76.
When consider together both indirect METHODS: sensibility
50%, speciﬁcity 89%, likelihood ratio for positive result 4.54.
CONCLUSION: Indirect methods for compliance assessment are
valid and applicable in clinical follow-up of patients with COPD.
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OBJECTIVES: The objective of this study was to examine the
impact of salmeterol/ﬂuticasone propionate combination (SFC)
on the health related quality of life (HRQOL) of patients with
respiratory diseases. HRQOL data is not often collected when
examining the impact of treatment in Ireland eventhough
improving HRQOL is one of the main objectives of treatment of
chronic diseases. METHODS: This was a non-interventional,
observational cohort study that recruited 113 patients attending
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15 different GP practices across Ireland who were deemed suit-
able by their physician to start treatment with SFC (any dose).
HRQOL was assessed using the SF-36 before treatment and 12
weeks later following treatment. RESULTS: Data was evaluable
for 90 patients (71%; asthma, 21%; COPD, 8%; bronchitis or
cough). Fifty-four percent of patients were female and 33% were
over 60 years of age. At baseline, HRQOL scores for all health
attributes for all patients was less than that of the general popu-
lation. The biggest difference was in the role physical and general
health attributes (37 and 24 points respectively). After 12 weeks,
SFC had a signiﬁcant positive impact on most health attributes.
The biggest improvements were observed in the role physical,
vitality, social functioning and role emotional attributes with an
average difference of 15.5, 11.5, 11.1 and 10.9 points respec-
tively (all p < 0.004). CONCLUSION: This study showed that
respiratory diseases have a negative impact on patient’s quality of
life. However, treatment with SFC resulted in positive improve-
ments in the quality of life of patients with respiratory diseases
like asthma and COPD.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD)
imposes a tremendous economic and humanistic burden on
health care systems worldwide. The EQ-5D is a generic measure
of health-related quality of life (HRQL) that can help to better
understand the impact of COPD. The aim of this study was to
estimate EQ-5D index-based utility scores associated with differ-
ent levels of severity of COPD according to Global initiative of
Chronic Obstructive Lung Disease (GOLD) stage. METHODS:
A structured literature search was conducted in EMBASE and
MEDLINE (Jan 1988 to Jan 2007) using keywords relevant to
respiratory disease and EQ-5D. Original research studies in
COPD that reported EQ-5D summary scores were selected for
inclusion. Pooled summary scores for UK-based index were esti-
mated using a ﬁxed-effects estimate for COPD overall and by
GOLD stage (Stage I [least severe] to Stage IV [most severe]).
RESULTS: Of 15 original research studies identiﬁed prior to
screening, 8 reported EQ-5D index-based summary scores by
severity. Utility scores which ranged from 0.52 (SD 0.16) to 0.84
(SD 0.15). Pooled average utility scores (95% CI) by GOLD
stage were as follows: stage I = 0.74 (0.62–0.87); stage II = 0.74
(0.66–0.83); stage III = 0.69 (0.60–0.78); and stage IV = 0.61
(0.44–0.77). CONCLUSION: Synthesis of the current literature
provided evidence that HRQL decreases with severity of COPD.
Utilities associated with stage of severity may be useful for
modeling outcomes and facilitating quality-adjusted life-year
calculations in economic evaluations of COPD.
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OBJECTIVES: To model the relationship between St George’s
Respiratory Questionnaire for Chronic Obstructive Pulmonary
Disease (SGRQ-COPD) and utilities based on EQ-5D so as
to estimate preference-based utilities for COPD patients.
METHODS: Dataset comprised of a one-year clinical study of
845 patients. 559 patients completed all items of the SGRQ-
COPD and EQ-5D at baseline. Ordinary least squares regression
was used to predict EQ-5D utilities based on responses to SGRQ-
COPD. Following identiﬁcation of signiﬁcant patient character-
istics, signiﬁcant components and individual items measured in
SGRQ-COPD were included using stepwise selection regression
with an additive speciﬁcation to obtain the preferred algorithm
to explain EQ-5D utilities. Adjusted R-squared and error of
prediction (root mean-squared error: RMSE), were used to judge
goodness of ﬁt. The preferred algorithm was validated for pre-
dictive ability using end of trial data. RESULTS: The preferred
algorithm included the following terms (coefﬁcient): constant
(+1.0050), symptoms (-0.0006), activity (-0.0019) and impacts
(+0.0019) component scores, one activity item—Item 27 ‘I take a
long time to get washed or dressed’ (-0.0780), one symptom
item—Item 5—‘I have had 3 or more attacks of chest trouble in
the last year’ (-0.0480), and two patient characteristics, smoking
history (-0.0160) and gender (+0.0304). Adjusted R-squared
was 43.45% and RMSE was 0.1452. In the validation analysis,
this algorithm explained 39% of the variation in utilities derived
from EQ-5D. The algorithm that excluded items 27 and 5, but
included all three components and two patient characteristics,
had adjusted R-squared of 41.11% and RMSE of 0.1482. Alter-
native speciﬁcations applying a logistic transformation and Tobit
regression did not improve on this model. CONCLUSION: The
regression model enables utilities to be estimated for study
patients with SGRQ-COPD measurements but for whom
no preference-based instrument has been administered. The
approach appears fairly robust based on the explanatory power
of the algorithm and validation results.
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United BioSource Corporation, London, UK
OBJECTIVES: Agencies such as NICE in the UK have speciﬁc
requirements for economic evaluations. NICE specify how utility
data should be collected and used in such analyses. The present
review aimed to: 1) identify which utility measures have been
used in asthma and COPD; 2) compare their measurement
properties; and 3) determine if they meet NICE requirements.
METHODS: A literature (Embase, PubMed) and internet
(Google, PROQOLID) search for studies including utility mea-
sures in asthma and COPD was completed for the last 10 years.
It identiﬁed 41 and 24 studies respectively. The evidence regard-
ing each measure was critically appraised and summarised in
terms of our three criteria. RESULTS: Asthma and COPD search
generated 41 and 24 hits respectively. The following generic
instruments had been used in asthma or COPD studies: EQ-5D,
15D, HUI-2, SF-6D [1]. Disease speciﬁc utility measures were
also identiﬁed: ALQ-5D, Asthma Symptoms Utility Index (ASUI)
and the SGRQ-U. The ALQ-5D and the SGRQ-U are derived
from the Asthma Quality of life Questionnaire and St Georges
Respiratory Questionnaire respectively. The EQ-5D has been
most commonly used and one comparison study found it to be
more sensitive than the SF-6D. Measurement properties and
appropriateness for all measures will be summarised. CONCLU-
SION: Utility measures have been quite widely used in asthma
and COPD. EQ-5D, SF-6D, ALQ-5D and HUI-2 would all in
principle be suitable for NICE, but EQ-5D is probably the safest
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